PRR5-ARHGAP8

Across TCGA pan-cancer cohorts, PRR5-ARHGAP8 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated PRR5-ARHGAP8 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PRR5-ARHGAP8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRR5-ARHGAP8 expression acts as an unfavorable survival marker.

ESCA, LUAD, and HNSC are the cancer types where PRR5-ARHGAP8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
LUAD	OS	Median	II,III,IV	0.053	0.751	<.001	30	view →
HNSC	DFS	Median	All	0.163	0.696	.007	24	view →
LUSC	OS	Median	II,III,IV	0.123	0.746	<.001	24	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
STAD	OS	Median	IV	0.075	0.496	.013	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.136	0.708	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PRR5-ARHGAP8–ESCA (OS)

Open the ESCA breakdown →